IDT Expands Gene Expression Assay Portfolio to Better Support Validation and Screening Studies

Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, expands its PrimeTime qPCR portfolio to include new assay scales that enable more affordable gene expression studies. The PrimeTime Mini (100 reactions), Standard (500 reactions) and XL (2500 reactions) Assay scales better reflect customer needs for validation and screening studies.

Stephen Gunstream, IDT’s OEM Business Unit Leader commented, “Our new qPCR scales ensure that all scientists, including those who only require limited reactions, can have access to the most precise quantitative PCR chemistry available.”

The new assays can be ordered through IDT’s RealTime PCR Design Tool. The tool allows for ultimate design flexibility and includes the option to select specific exon spanning sites, as well as review all primer and probe sequences prior to purchase.